Haemonetics Corporation $HAE Shares Acquired by Rhumbline Advisers

Rhumbline Advisers boosted its stake in Haemonetics Corporation (NYSE:HAE) by 1.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 161,123 shares of the medical instruments supplier’s stock after buying an additional 1,861 shares during the quarter. Rhumbline Advisers owned approximately 0.34% of Haemonetics worth $10,239,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Quarry LP lifted its holdings in Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 192 shares in the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Haemonetics during the 1st quarter worth approximately $65,000. Strs Ohio purchased a new stake in shares of Haemonetics in the first quarter valued at approximately $140,000. KBC Group NV increased its holdings in shares of Haemonetics by 19.9% in the first quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier’s stock valued at $154,000 after purchasing an additional 401 shares during the last quarter. Finally, AlphaQuest LLC lifted its position in Haemonetics by 71.5% during the first quarter. AlphaQuest LLC now owns 3,140 shares of the medical instruments supplier’s stock worth $200,000 after buying an additional 1,309 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $53.61 on Thursday. The business has a 50-day simple moving average of $64.73 and a 200-day simple moving average of $65.55. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72. Haemonetics Corporation has a one year low of $50.68 and a one year high of $94.99. The company has a market cap of $2.58 billion, a PE ratio of 16.40, a P/E/G ratio of 1.00 and a beta of 0.39.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company had revenue of $321.39 million during the quarter, compared to the consensus estimate of $305.12 million. During the same quarter in the previous year, the firm earned $1.02 earnings per share. The firm’s quarterly revenue was down 4.4% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, equities research analysts forecast that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Analysts Set New Price Targets

HAE has been the topic of several analyst reports. Mizuho reduced their price target on Haemonetics from $90.00 to $70.00 and set an “outperform” rating on the stock in a report on Friday, August 8th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $62.00 target price (down from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Raymond James Financial cut Haemonetics from a “strong-buy” rating to an “outperform” rating and decreased their price objective for the company from $105.00 to $78.00 in a report on Monday, August 11th. Baird R W raised Haemonetics to a “strong-buy” rating in a research note on Wednesday, June 25th. Finally, Citigroup upgraded Haemonetics from a “neutral” rating to a “buy” rating and set a $90.00 target price on the stock in a research report on Wednesday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $82.50.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.